Main Article Content
To explore the new ophthalmic dosage forms of ganciclovir which are suitable for development, and to evaluate its physical and chemical experiments before development. The absorption of drugs in the eye was discussed, and the suitable dosage forms that can increase the solubility of drugs, prolong the retention time and increase the corneal transmittance of drugs were discussed. The physical and chemical properties needed for drug development were evaluated, and the methods for determining ganciclovir by ultraviolet spectrophotometry were established. The ultraviolet methods for determining the solubility and oil/water partition coefficient of ganciclovir were established. The solubility of ganciclovir in different aqueous media and the partition coefficient of ganciclovir in oil/water system composed of n-octanol and different aqueous media were determined. To determine the theoretical basis for the next dosage form development experiment. The liposome in situ gel developed by ganciclovir can significantly prolong the retention time of the drug in the eye and increase the corneal permeability of the drug. The development of microemulsion gel can also play a better sustained-release effect. Liposome in situ gel is more advantageous than microemulsion gel for the corneal transmittance of ganciclovir in the eye, which is more conducive to improving the effect of ganciclovir and reducing the waste in the use of ophthalmic preparations. Ganciclovir is more suitable to be developed into liposome in-situ gel. The established ultraviolet spectrophotometry method for determining Ganciclovir can accurately and quickly determine Ganciclovir. The established ultraviolet method for determining the solubility and oil/water partition coefficient of Ganciclovir can be used for drug in vitro determination. The determination of the solubility of Ganciclovir in different aqueous media and the partition coefficient of Ganciclovir in oil/water system composed of n-octanol and different aqueous media provide theoretical basis for the next development of prescription screening.